KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Non-Current Assets: 2017-2025

Historic Non-Current Assets for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $5.5 billion.

  • Moderna's Non-Current Assets fell 9.78% to $5.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 billion, marking a year-over-year decrease of 9.78%. This contributed to the annual value of $6.0 billion for FY2024, which is 25.40% down from last year.
  • As of Q3 2025, Moderna's Non-Current Assets stood at $5.5 billion, which was down 5.17% from $5.8 billion recorded in Q2 2025.
  • In the past 5 years, Moderna's Non-Current Assets registered a high of $12.5 billion during Q2 2022, and its lowest value of $991.0 million during Q1 2021.
  • Its 3-year average for Non-Current Assets is $7.5 billion, with a median of $6.1 billion in 2024.
  • Per our database at Business Quant, Moderna's Non-Current Assets skyrocketed by 1,036.13% in 2022 and then tumbled by 46.66% in 2024.
  • Moderna's Non-Current Assets (Quarterly) stood at $8.6 billion in 2021, then surged by 44.53% to $12.4 billion in 2022, then tumbled by 34.81% to $8.1 billion in 2023, then dropped by 25.40% to $6.0 billion in 2024, then dropped by 9.78% to $5.5 billion in 2025.
  • Its Non-Current Assets stands at $5.5 billion for Q3 2025, versus $5.8 billion for Q2 2025 and $5.9 billion for Q1 2025.